Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, announced the closing of a securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering. The offering generated gross proceeds of approximately $2.0 million for the company.
D. Boral Capital LLC served as the exclusive placement agent for the offering, which was conducted pursuant to the company’s effective shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. The full press release is available at https://ibn.fm/o5A0w.
Jupiter Neurosciences is advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The company’s lead program, JOTROL™, a proprietary enhanced bioavailability resveratrol formulation, is currently in a Phase IIa clinical trial for Parkinson’s disease. Additionally, the company commercializes Nugevia™, a consumer longevity supplement, and recently acquired U.S. rights to ALA-002, a next-generation, patented psychedelic NCE that strengthens its CNS pipeline at a pivotal moment in U.S. regulatory policy.
The successful closing of this offering provides Jupiter Neurosciences with additional capital to support its ongoing clinical trials and development efforts. For investors, this move signals the company's ability to secure funding in a challenging biotech market, potentially accelerating the timeline for its lead programs. The funds are expected to be used for general corporate purposes, including research and development activities.
This offering is part of a broader trend in the biopharmaceutical industry where small-cap companies are leveraging registered direct offerings to raise capital efficiently. The impact on the industry could be significant as Jupiter continues to develop treatments for neurodegenerative diseases, which affect millions worldwide. The additional funding may help bring JOTROL™ closer to regulatory approval, offering new hope for Parkinson’s disease patients.
For more information about Jupiter Neurosciences, visit www.jupiterneurosciences.com. This announcement underscores the company’s commitment to addressing unmet medical needs in CNS disorders.
